| Assessment Status | Rapid Review Complete |
| HTA ID | 22074 |
| Drug | Tixagevimab/cilgavimab |
| Brand | Evusheld® |
| Indication | Is indicated for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. |
| Assessment Process | |
| Rapid review commissioned | 12/12/2022 |
| Rapid review completed | 25/01/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tixagevimab/cilgavimab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.